H

Hualan Biological Bacterin Inc
SZSE:301207

Watchlist Manager
Hualan Biological Bacterin Inc
SZSE:301207
Watchlist
Price: 21.74 CNY -1.09% Market Closed
Market Cap: 13.1B CNY

Hualan Biological Bacterin Inc
Gross Profit

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Hualan Biological Bacterin Inc
Gross Profit Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Gross Profit CAGR 3Y CAGR 5Y CAGR 10Y
H
Hualan Biological Bacterin Inc
SZSE:301207
Gross Profit
ÂĄ841m
CAGR 3-Years
-17%
CAGR 5-Years
0%
CAGR 10-Years
N/A
Beigene Ltd
HKEX:6160
Gross Profit
ÂĄ23B
CAGR 3-Years
52%
CAGR 5-Years
56%
CAGR 10-Years
N/A
Innovent Biologics Inc
HKEX:1801
Gross Profit
ÂĄ9.8B
CAGR 3-Years
37%
CAGR 5-Years
47%
CAGR 10-Years
N/A
Akeso Inc
HKEX:9926
Gross Profit
ÂĄ1.8B
CAGR 3-Years
111%
CAGR 5-Years
91%
CAGR 10-Years
N/A
3SBio Inc
HKEX:1530
Gross Profit
ÂĄ7.7B
CAGR 3-Years
14%
CAGR 5-Years
12%
CAGR 10-Years
N/A
S
Sichuan Kelun-Biotech Biopharmaceutical Co Ltd
HKEX:6990
Gross Profit
ÂĄ1.3B
CAGR 3-Years
376%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Hualan Biological Bacterin Inc
Glance View

Market Cap
13.1B CNY
Industry
Biotechnology

In the bustling landscape of biotechnology, Hualan Biological Bacterin Inc. emerges as a formidable player. This Chinese company, rooted in the province of Henan, has carved its niche in the development and manufacture of human vaccines. Hualan's journey began with a focused vision on advancing public health through immunization. Today, it stands among the largest producers of human vaccines in China, adeptly navigating the stringent regulatory environments that govern this critical sector. The company's innovative approach in vaccine research is bolstered by state-of-the-art facilities and an unwavering commitment to quality, enabling it to produce safe, effective, and affordable vaccines. Over the years, Hualan has expanded its portfolio to include vaccines for influenza, rabies, and measles, to name a few, each product carefully developed to meet domestic and international health needs. Hualan Biological Bacterin Inc. generates its revenues substantially through the sale of these vaccines. The company's business model leans heavily on its strong distribution network, which ensures that its products effectively reach healthcare providers and institutions across China. Regulatory approvals for new vaccines further pave the way for market expansion and potential export opportunities, contributing to revenue growth. Furthermore, the company strategically invests in research and development, consistently working on new immunological breakthroughs, thus securing its standing and paving the way for future revenue streams. Through this meticulous combination of development, regulatory savvy, and strategic distribution, Hualan not only sustains its financial health but continues to play a vital role in advancing global public health.

Intrinsic Value
27.61 CNY
Undervaluation 21%
Intrinsic Value
Price
H

See Also

What is Hualan Biological Bacterin Inc's Gross Profit?
Gross Profit
841m CNY

Based on the financial report for Dec 31, 2024, Hualan Biological Bacterin Inc's Gross Profit amounts to 841m CNY.

What is Hualan Biological Bacterin Inc's Gross Profit growth rate?
Gross Profit CAGR 5Y
0%

Over the last year, the Gross Profit growth was -59%. The average annual Gross Profit growth rates for Hualan Biological Bacterin Inc have been -17% over the past three years .

Back to Top